Trilegal advised Edelweiss Alternative Asset Advisors Limited (Edelweiss) and ESOF III Investment Fund (sponsored and managed by Edelweiss Alternatives) on their investment in (i) non-convertible debentures issued by Biocon Limited, a listed fully integrated biopharmaceutical company, aggregating up to INR 500 crores; and (ii) compulsorily convertible debentures to be issued by Biocon Biologics Limited, a subsidiary of Biocon Limited which develops biosimilars, aggregating up to INR 300 crores.
The deal was led by corporate partners Kabeer Mathur and Kunal Chandra and banking and finance partners Aniruddha Sen and Prasan Dhar.
They were supported by attorneys including Surbhi Jaju, and Parthasarathi Das (Senior Associates); Chinmay Bilgi, Nezhat Fouzdar, Dhaval Mehta, Disha Rathod, Harshit Dhandhia, Prahalad Naganath, Lakshya Singla and Navolina Majumdar (Associates).
Trilegal is one of India’s leading law firms, with expertise across the full spectrum of corporate legal services. Trilegal has offices in four key cities of India.
Trilegal has been recognised as the India Deal Firm of the Year by Asian Legal Business (ALB) India Law Awards 2023; one of the ‘Best Overall Law Firms’ at the India Business Law Journal Indian Law Firm Awards 2022; ‘Firm of the year’ for Client Service Excellence by Asia Law Awards 2021; “M&A Law firm of the Year” by VCCircle Awards 2020 one of the most innovative law firms in Asia in the inaugural edition of ALB Trailblazers 2020; and ‘highly commended’ in the FT RSG Innovative Lawyers Awards 2020.
For more information, please contact:
Under the rules of the Bar Council of India, Trilegal is prohibited from soliciting work or advertising in any form or manner. By accessing this website, www.trilegal.com, you acknowledge that: